RECURRENT CENTRAL NERVOUS SYSTEM LYMPHOMA
Clinical trials for RECURRENT CENTRAL NERVOUS SYSTEM LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT CENTRAL NERVOUS SYSTEM LYMPHOMA trials appear
Sign up with your email to follow new studies for RECURRENT CENTRAL NERVOUS SYSTEM LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Engineered immune cells take aim at Hard-to-Treat lymphomas
Disease control OngoingThis study tests a treatment made from a patient's own immune cells, which are genetically modified to recognize and attack a protein called CD20 on cancer cells. It is for people with B-cell non-Hodgkin lymphoma that has returned or not responded to prior therapy. The main goals…
Matched conditions: RECURRENT CENTRAL NERVOUS SYSTEM LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New hope for brain lymphoma: acalabrutinib trial underway
Disease control OngoingThis phase 1/2 trial tests the drug acalabrutinib (Calquence) in 49 people with central nervous system lymphoma that has come back or not responded to treatment. Participants take the tablet by mouth twice daily. The study aims to find the safest dose and see if the drug can shri…
Matched conditions: RECURRENT CENTRAL NERVOUS SYSTEM LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC